Alnylam partnered with IQVIA Technologies to strengthen rare disease trials through the Investigator Site Portal, enabling seamless communication, study conduct, and site engagement. Since 2014, the portal has supported site activation, training, document exchange, and safety alerts, fostering trust with investigators. During COVID-19, it helped assess site needs, manage resources, and maintain enrollment, while tools like a customized Blood Volume Calculator safeguarded young patients. Features such as real-time Pre-ID logs and enrollment leaderboards improved recruitment. This collaboration accelerated Alnylam’s RNAi pipeline, contributing to approvals of multiple therapies while reducing CRA burden and protocol deviations.

Join for free to read